Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease

@inproceedings{Lee2017CosteffectivenessOC,
  title={Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease},
  author={Spencer A W Lee and Luciano A Sposato and Vladimir Hachinski and Lauren E. Cipriano},
  booktitle={Alzheimer's Research & Therapy},
  year={2017}
}
BackgroundAccurate and timely diagnosis of Alzheimer’s disease (AD) is important for prompt initiation of treatment in patients with AD and to avoid inappropriate treatment of patients with false-positive diagnoses.MethodsUsing a Markov model, we estimated the lifetime costs and quality-adjusted life-years (QALYs) of cerebrospinal fluid biomarker analysis in a cohort of patients referred to a neurologist or memory clinic with suspected AD who remained without a definitive diagnosis of AD or… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 67 REFERENCES

cost utility evaluation Lee et al

R Søgaard, J Sørensen, +4 authors disease et al. Early psychosocial intervention in Alzheimer’s
  • Alzheimer's Research & Therapy
  • 2017

evidence from Canada

G Payne, A Laporte, DK Foot, dying Coyte PC. Temporal trends in the relative cost of
  • Health Policy. 2009;90:270–6. • We accept pre-submission inquiries • Our selector tool helps you to find the most relevant journal • We provide round the clock customer support • Convenient online submission • Thorough peer review • Inclusion in PubMed and all major indexing services • Maximum visi
  • 2017
VIEW 1 EXCERPT